Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy

ConclusionOn average the relative percentage difference between the cumulated activities and absorbed dose of the two software were 10.7%.
Source: Health and Technology - Category: Information Technology Source Type: research